Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FGF23 | Q9GZV9 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358162 | 1.00 | NPC1 (0.54) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL12147812 | 0.76 | GAA (0.58) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9901402 | 0.76 | NPC1 (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL9901401 | 0.76 | NPC1 (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL506938 | 0.75 | RAB9A (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL4320351 | 0.75 | NPC1 (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL68190 | 0.75 | NPC1 (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL77711 | 0.75 | NPC1 (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL30592835 | 0.75 | RAB9A (0.46) | NPC1RAB9AKMT2AMEN1CASP3 | |
| SCHEMBL506939 | 0.75 | RAB9A (0.46) | NPC1RAB9AKMT2AMEN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-117285525-A | Novel isoxazolyl ether derivatives as GABAA alpha 5PAM | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| CN-109923113-B | Isoxazolyl ether derivatives as GABA A alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-112424196-A | Novel isoxazolyl ether derivatives as GABAA alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2350077-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-08-03 | — | — | EP | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7452892-B2 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2006138734-A1 | TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | NPC1 2500/4885RAB9A 855/4885KMT2A 1248/4885 |
| US-20060287341-A1 | Triazolopyrimidine cannabinoid receptor 1 antagonists | CNR1, CNR2, GPR68 | NPC1 1139/4885RAB9A 2633/4885KMT2A 2769/4885 |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | NPC1 4696/4885RAB9A 2952/4885KMT2A 2788/4885 |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | NPC1 2771/4885RAB9A 1461/4885KMT2A 1157/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | NPC1 3962/4885RAB9A 1164/4885KMT2A 831/4885 |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | NPC1 750/4885RAB9A 1618/4885KMT2A 3271/4885 |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA1, GABRA3 | NPC1 2301/4885RAB9A 1394/4885KMT2A 1433/4885 |
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | NPC1 2771/4885RAB9A 1461/4885KMT2A 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.